Neuralink launches first clinical study in Great Britain

Published 31/07/2025, 16:16
Neuralink launches first clinical study in Great Britain

Investing.com -- Neuralink has received approval to begin its first clinical study in Great Britain, called GB-PRIME, the company announced on Thursday.

The brain-computer interface (BCI) developer secured approvals from the Medicines and Healthcare products Regulatory Agency, the Health Research Authority and Health and Care Research Wales, and the London – Camberwell St Giles Research Ethics Committee.

The clinical study will evaluate the safety of Neuralink’s fully-implantable, wireless brain-computer interface and surgical robot, while also assessing the initial functionality of the technology. The BCI is designed to allow people with severe paralysis to control devices and interact with the digital world using only their thoughts.

GB-PRIME will be conducted at two locations: University College London Hospitals NHS Foundation Trust and The Newcastle upon Tyne Hospitals NHS Foundation Trust. The study builds on Neuralink’s ongoing PRIME trial in the United States.

The company is currently recruiting participants who are residents of Great Britain with limited or no ability to use both hands due to conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, or other neurological disorders.

Interested individuals can join Neuralink’s Patient Registry and learn more about the trial through the company’s website.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.